Measurable residual disease (MRD) and survival outcomes in patients with acute myeloid leukemia (AML)

MRD assessment

MRD assessment in AML can be used as a prognostic/predictive biomarker to inform treatment decision making and as a monitoring tool to identify impending relapse¹



MRD assessments are employed to evaluate leukemic burden at diagnosis and following treatment in several hematologic diseases; this role is well established in ALL and CLL²⁻⁴

MRD assessments detect leukemic burden when there are too few leukemic cells to be identified through traditional morphologic detection⁵


~1:20 Sensitivity of morphology-based testing to determine CR⁵

~10⁻² to ~10⁻⁶ Sensitivity of assays to determine MRD negativity^{5,6}

Common methods of assessing MRD in AML^{5,6,12}



Current guidelines for MRD testing in AML clinical trials



Abbreviations: MRD, measurable residual disease; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CL, chronic lymphoblastic leukemia; CR, complete remission; FISH, fluorescence in situ hybridization; NGS, next-generation sequencing; RT-qPCR, quantitative reverse transcription polymerase chain reaction; CHIP, clonal hematopoiesis of indeterminate potential; APL, acute promyelocytic leukemia; HCT, hematopoietic cell transplantation; FDA, US Food and Drug Administration; ELN, European Leuke PCR, polymerase chain reaction


Footnotes: "Patients with mutant NPM1, CBF AML (RUNX1-RUNX1T1 or CBFB-MYH11), or APL (PML-RARA) should have molecular assessment of MRD; AML patients not included in these molecularly defined subgroups should have MRD assessment using MFC. ^bIn APL, the most important MRD endpoint is PCR negativity for PML-RARA at the end of consolidation; for non-high-risk APL, MRD monitoring may be discontinued once MRD-negativity in bone marrow is achieved. Except for cytogenetics and FISH

References: 1. Heuser M, et al. Blood. 2021;138(26):2753-2767. 2. Brüggemann M, Kotrova M. Blood Adv. 2017;1(25):2456-2466. 3. Jen EY, et al. Clin Cancer Res. 2019;25(2):473-477. 4. Del Giudice I, et al. Front Oncol. 2019;9:689 5. Ravandi F, et al. Blood Adv. 2018;2(11):1356-1366. 6. Jentzsch M, et al. Cancers. 2019;11(11):1625. 7. Short NJ, et al. JAMA Oncol. 2020;6(12):1890-1899. 8. Araki D, et al. J Clin Oncol. 2016;34(4):329-336. 9. lvey A, et al. N Engl J Med. 2016;374(5):422-433 10. US Food and Drug Administration. Hematologic malignancies: regulatory considerations for use of minimal residual disease in development of drug and biological products for treatment. January 2020. https://www.fda.gov/regulatory-information/search-fda-guid-ance-documents/hematologic-malignancies-regulatory-considerations-use-minimal-residual-disease-development-drug-and. Accessed April 2022. 11. Schuurhuis GJ, et al. *Blood*. 2018;131(12):1275-1291. 12. Short NJ, Ravandi F. *Haematologica*. 2019;104(8):1532-1541



Predictive value of MRD in AML

MRD negativity in patients with AML is associated with improved overall and disease-free survival, lower risk of relapse, and greater success of HCT⁷⁻⁹



consistent across age groups, AML subtypes, and most MRD detection methods^{7,c}

Reproduced with permission from JAMA Oncology. 2020;6(12):1890-1899. Copyright ©2020 American Medical Association. All rights reserved

> © 2023 Jazz Pharmaceuticals M-INT-OHD-2300046 Date of preparation: March 2023

Jazz Pharmaceuticals

